{
    "xml": "<topic id=\"PHP5724\" outputclass=\"drug\" rev=\"1.18\" type=\"drug\" namespace=\"/drugs/natalizumab\" basename=\"natalizumab\" title=\"NATALIZUMAB\">\n<title>NATALIZUMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1339\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/natalizumub\">Natalizumub</xref>\n</p>\n<data name=\"vtmid\">414804006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_402717286\" title=\"Monoclonal antibodies (anti-lymphocyte)\">Monoclonal antibodies (anti-lymphocyte)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP34911\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/natalizumab\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Natalizumab is a monoclonal antibody that inhibits the migration of leucocytes into the central nervous system, hence reducing inflammation and demyelination.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62229\" outputclass=\"indicationsAndDose\" rev=\"1.25\" parent=\"/drugs/natalizumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Highly active relapsing-remitting multiple sclerosis despite treatment with interferon beta or glatiramer acetate, or those patients with rapidly evolving severe relapsing-remitting multiple sclerosis (initiated under specialist supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>300&#8239;mg every 4&#8239;weeks, treatment should be discontinued if no response after 6 months.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35291\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/natalizumab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active infection</ph>; <ph outputclass=\"contraindication\">active malignancies (except cutaneous basal cell carcinoma)</ph>; <ph outputclass=\"contraindication\">immunosuppression</ph>; <ph outputclass=\"contraindication\">progressive multifocal leucoencephalopathy</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35453\" outputclass=\"cautions\" rev=\"1.44\" parent=\"/drugs/natalizumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Progressive Multifocal Leucoencephalopathy</p>\n<p>Natalizumab is associated with an increased risk of opportunistic infection and progressive multifocal leucoencephalopathy (PML) caused by JC virus. The risk of developing PML increases with the presence of anti-JCV antibodies, previous use of immunosuppressant therapy, and treatment duration (especially beyond 2 years of treatment); the risk beyond 4 years of treatment is not known. Patients with all three risk factors should only be treated with natalizumab if the benefits of treatment outweigh the risks. Treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued.</p>\n</sectiondiv>\n<sectiondiv>\n<p>For information on cautions consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62080\" outputclass=\"interactions\" rev=\"1.20\" parent=\"/drugs/natalizumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (natalizumab).</p>\n</sectiondiv>\n<sectiondiv>\n<p>Concurrent use of interferon beta or glatiramer acetate contra-indicated.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61335\" outputclass=\"sideEffects\" rev=\"1.29\" parent=\"/drugs/natalizumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arthralgia</ph>; <ph outputclass=\"sideEffect\">autoantibodies</ph>; <ph outputclass=\"sideEffect\">nasopharyngitis</ph>; <ph outputclass=\"sideEffect\">urinary-tract infection</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hypersensitivity reactions (discontinue permanently)</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arthralgia (during infusion)</ph>; <ph outputclass=\"sideEffect\">dizziness (during infusion)</ph>; <ph outputclass=\"sideEffect\">fatigue (during infusion)</ph>; <ph outputclass=\"sideEffect\">flushing (during infusion)</ph>; <ph outputclass=\"sideEffect\">headache (during infusion)</ph>; <ph outputclass=\"sideEffect\">increased risk of opportunistic infection</ph>; <ph outputclass=\"sideEffect\">liver toxicity</ph>; <ph outputclass=\"sideEffect\">nausea (during infusion)</ph>; <ph outputclass=\"sideEffect\">pruritus (during infusion)</ph>; <ph outputclass=\"sideEffect\">pyrexia (during infusion)</ph>; <ph outputclass=\"sideEffect\">rigors (during infusion)</ph>; <ph outputclass=\"sideEffect\">urticaria (during infusion)</ph>; <ph outputclass=\"sideEffect\">vomiting (during infusion)</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Progressive Multifocal Leucoencephalopathy</p>\n<p>If Progressive Multifocal Leucoencephalopathy (PML) is suspected, treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Liver toxicity</p>\n<p>Discontinue treatment if significant liver injury occurs.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61877\" outputclass=\"pregnancy\" parent=\"/drugs/natalizumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless essential&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35553\" outputclass=\"breastFeeding\" parent=\"/drugs/natalizumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk in <i>animal</i> studies&#8212;avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61443\" outputclass=\"preTreatmentScreening\" rev=\"1.16\" parent=\"/drugs/natalizumab\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Progressive Multifocal Leucoencephalopathy</p>\n<p>A magnetic resonance image (MRI) scan is recommended before starting treatment with natalizumab.</p>\n<p>Testing for serum anti-JCV antibodies before starting treatment or in those with unknown antibody status already receiving natalizumab is recommended and should be repeated every 6 months (consult product literature for full details).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60782\" outputclass=\"monitoringRequirements\" parent=\"/drugs/natalizumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor liver function.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Progressive Multifocal Leucoencephalopathy</p>\n<p>A magnetic resonance image (MRI) scan is recommended annually. Patients should be monitored for new or worsening neurological symptoms, and for cognitive and psychiatric signs of PML.</p>\n<p>All patients should continue to be monitored for signs and symptoms that may be suggestive of PML for approximately 6 months following discontinuation of treatment.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions</p>\n<p>Patients should be observed for hypersensitivity reactions, including anaphylaxis, during the infusion and for 1 hour after completion of the infusion.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35890\" outputclass=\"directionsForAdministration\" rev=\"1.18\" parent=\"/drugs/natalizumab\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>For <i>intravenous infusion</i> (<i>Tysabri</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9%; dilute 300&#8239;mg in 100&#8239;mL infusion fluid; gently invert to mix, do not shake. Use within 8 hours of dilution and give over 1 hour.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61773\" outputclass=\"patientAndCarerAdvice\" rev=\"1.26\" parent=\"/drugs/natalizumab\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p>A patient alert card should be provided.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions</p>\n<p>Patients should be told the importance of uninterrupted dosing, particularly in the early months of treatment (intermittent therapy may increase risk of sensitisation).</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Progressive Multifocal Leucoencephalopathy</p>\n<p>Patients should be informed about the risks of PML before starting treatment with natalizumab and again after 2 years; they should be given an alert card which includes information about the symptoms of PML.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Liver toxicity</p>\n<p>Advise patients to seek immediate medical attention if symptoms such as jaundice or dark urine develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60317\" outputclass=\"nationalFunding\" rev=\"1.20\" parent=\"/drugs/natalizumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA127</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (August 2007)</p>\r\n<p>Natalizumab is an option for the treatment only of rapidly evolving severe relapsing-remitting multiple sclerosis (RES). RES is defined by 2 or more disabling relapses in 1 year, and 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA127\">www.nice.org.uk/TA127</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (August 2007) that natalizumab is accepted for restricted use as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis only in patients with rapidly evolving severe relapsing-remitting multiple sclerosis defined by 2 or more disabling relapses in 1 year and with 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5724-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/natalizumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75113\" title=\"Solution for infusion\" namespace=\"/drugs/natalizumab/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1339\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/natalizumub\" title=\"Natalizumub\" count=\"1\" rel=\"link\">Natalizumub</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75113\" namespace=\"/drugs/natalizumab/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5724",
    "outputclass": "drug",
    "rev": "1.18",
    "type": "drug",
    "namespace": "/drugs/natalizumab",
    "basename": "natalizumab",
    "title": "NATALIZUMAB",
    "interactants": [
        {
            "id": "bnf_int_1339",
            "label": "Natalizumub"
        }
    ],
    "vtmid": "414804006",
    "drugClassification": [
        "Monoclonal antibodies (anti-lymphocyte)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Natalizumab is a monoclonal antibody that inhibits the migration of leucocytes into the central nervous system, hence reducing inflammation and demyelination.",
                "html": "<p>Natalizumab is a monoclonal antibody that inhibits the migration of leucocytes into the central nervous system, hence reducing inflammation and demyelination.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Highly active relapsing-remitting multiple sclerosis despite treatment with interferon beta or glatiramer acetate, or those patients with rapidly evolving severe relapsing-remitting multiple sclerosis (initiated under specialist supervision)",
                        "html": "Highly active relapsing-remitting multiple sclerosis despite treatment with interferon beta or glatiramer acetate, or those patients with rapidly evolving severe relapsing-remitting multiple sclerosis (initiated under specialist supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "300 mg every 4 weeks, treatment should be discontinued if no response after 6 months.",
                        "html": "<p>300&#8239;mg every 4&#8239;weeks, treatment should be discontinued if no response after 6 months.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active infection",
                "html": "Active infection"
            },
            {
                "type": "contraindications",
                "textContent": "active malignancies (except cutaneous basal cell carcinoma)",
                "html": "active malignancies (except cutaneous basal cell carcinoma)"
            },
            {
                "type": "contraindications",
                "textContent": "immunosuppression",
                "html": "immunosuppression"
            },
            {
                "type": "contraindications",
                "textContent": "progressive multifocal leucoencephalopathy",
                "html": "progressive multifocal leucoencephalopathy"
            }
        ]
    },
    "cautions": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Progressive Multifocal Leucoencephalopathy",
                "textContent": "Natalizumab is associated with an increased risk of opportunistic infection and progressive multifocal leucoencephalopathy (PML) caused by JC virus. The risk of developing PML increases with the presence of anti-JCV antibodies, previous use of immunosuppressant therapy, and treatment duration (especially beyond 2 years of treatment); the risk beyond 4 years of treatment is not known. Patients with all three risk factors should only be treated with natalizumab if the benefits of treatment outweigh the risks. Treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued.",
                "html": "<p>Natalizumab is associated with an increased risk of opportunistic infection and progressive multifocal leucoencephalopathy (PML) caused by JC virus. The risk of developing PML increases with the presence of anti-JCV antibodies, previous use of immunosuppressant therapy, and treatment duration (especially beyond 2 years of treatment); the risk beyond 4 years of treatment is not known. Patients with all three risk factors should only be treated with natalizumab if the benefits of treatment outweigh the risks. Treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued.</p>"
            },
            {
                "type": "importantAdvice",
                "textContent": "For information on cautions consult product literature.",
                "html": "<p>For information on cautions consult product literature.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (natalizumab).",
                "html": "<p>Appendix 1 (natalizumab).</p>"
            },
            {
                "type": "general",
                "textContent": "Concurrent use of interferon beta or glatiramer acetate contra-indicated.",
                "html": "<p>Concurrent use of interferon beta or glatiramer acetate contra-indicated.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Arthralgia",
                        "html": "Arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "autoantibodies",
                        "html": "autoantibodies",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nasopharyngitis",
                        "html": "nasopharyngitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "urinary-tract infection",
                        "html": "urinary-tract infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Hypersensitivity reactions (discontinue permanently)",
                        "html": "Hypersensitivity reactions (discontinue permanently)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Arthralgia (during infusion)",
                        "html": "Arthralgia (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dizziness (during infusion)",
                        "html": "dizziness (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fatigue (during infusion)",
                        "html": "fatigue (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "flushing (during infusion)",
                        "html": "flushing (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache (during infusion)",
                        "html": "headache (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "increased risk of opportunistic infection",
                        "html": "increased risk of opportunistic infection",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "liver toxicity",
                        "html": "liver toxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea (during infusion)",
                        "html": "nausea (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pruritus (during infusion)",
                        "html": "pruritus (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pyrexia (during infusion)",
                        "html": "pyrexia (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rigors (during infusion)",
                        "html": "rigors (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "urticaria (during infusion)",
                        "html": "urticaria (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting (during infusion)",
                        "html": "vomiting (during infusion)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Progressive Multifocal Leucoencephalopathy",
                "textContent": "If Progressive Multifocal Leucoencephalopathy (PML) is suspected, treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued.",
                "html": "<p>If Progressive Multifocal Leucoencephalopathy (PML) is suspected, treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued.</p>"
            },
            {
                "type": "advice",
                "title": "Liver toxicity",
                "textContent": "Discontinue treatment if significant liver injury occurs.",
                "html": "<p>Discontinue treatment if significant liver injury occurs.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless essential&#8212;toxicity in animal studies.",
                "html": "<p>Avoid unless essential&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk in animal studies&#8212;avoid.",
                "html": "<p>Present in milk in <i>animal</i> studies&#8212;avoid.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "title": "Progressive Multifocal Leucoencephalopathy",
                "textContent": "A magnetic resonance image (MRI) scan is recommended before starting treatment with natalizumab.\n\nTesting for serum anti-JCV antibodies before starting treatment or in those with unknown antibody status already receiving natalizumab is recommended and should be repeated every 6 months (consult product literature for full details).",
                "html": "<p>A magnetic resonance image (MRI) scan is recommended before starting treatment with natalizumab.</p><p>Testing for serum anti-JCV antibodies before starting treatment or in those with unknown antibody status already receiving natalizumab is recommended and should be repeated every 6 months (consult product literature for full details).</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor liver function.",
                "html": "<p>Monitor liver function.</p>"
            },
            {
                "type": "patientParameters",
                "title": "Progressive Multifocal Leucoencephalopathy",
                "textContent": "A magnetic resonance image (MRI) scan is recommended annually. Patients should be monitored for new or worsening neurological symptoms, and for cognitive and psychiatric signs of PML.\n\nAll patients should continue to be monitored for signs and symptoms that may be suggestive of PML for approximately 6 months following discontinuation of treatment.",
                "html": "<p>A magnetic resonance image (MRI) scan is recommended annually. Patients should be monitored for new or worsening neurological symptoms, and for cognitive and psychiatric signs of PML.</p><p>All patients should continue to be monitored for signs and symptoms that may be suggestive of PML for approximately 6 months following discontinuation of treatment.</p>"
            },
            {
                "type": "patientParameters",
                "title": "Hypersensitivity reactions",
                "textContent": "Patients should be observed for hypersensitivity reactions, including anaphylaxis, during the infusion and for 1 hour after completion of the infusion.",
                "html": "<p>Patients should be observed for hypersensitivity reactions, including anaphylaxis, during the infusion and for 1 hour after completion of the infusion.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "For intravenous infusion (Tysabri ), give intermittently in Sodium chloride 0.9%; dilute 300 mg in 100 mL infusion fluid; gently invert to mix, do not shake. Use within 8 hours of dilution and give over 1 hour.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Tysabri</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9%; dilute 300&#8239;mg in 100&#8239;mL infusion fluid; gently invert to mix, do not shake. Use within 8 hours of dilution and give over 1 hour.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "textContent": "A patient alert card should be provided.",
                "html": "<p>A patient alert card should be provided.</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Hypersensitivity reactions",
                "textContent": "Patients should be told the importance of uninterrupted dosing, particularly in the early months of treatment (intermittent therapy may increase risk of sensitisation).",
                "html": "<p>Patients should be told the importance of uninterrupted dosing, particularly in the early months of treatment (intermittent therapy may increase risk of sensitisation).</p>"
            },
            {
                "type": "generalPatientAdvice",
                "title": "Progressive Multifocal Leucoencephalopathy",
                "textContent": "Patients should be informed about the risks of PML before starting treatment with natalizumab and again after 2 years; they should be given an alert card which includes information about the symptoms of PML.",
                "html": "<p>Patients should be informed about the risks of PML before starting treatment with natalizumab and again after 2 years; they should be given an alert card which includes information about the symptoms of PML.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "title": "Liver toxicity",
                "textContent": "Advise patients to seek immediate medical attention if symptoms such as jaundice or dark urine develop.",
                "html": "<p>Advise patients to seek immediate medical attention if symptoms such as jaundice or dark urine develop.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA127",
                        "label": "www.nice.org.uk/TA127"
                    }
                ],
                "fundingIdentifier": "NICE TA127",
                "textContent": "Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (August 2007) Natalizumab is an option for the treatment only of rapidly evolving severe relapsing-remitting multiple sclerosis (RES). RES is defined by 2 or more disabling relapses in 1 year, and 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.\n\nwww.nice.org.uk/TA127",
                "html": "<p outputclass=\"title\">Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (August 2007)</p> <p>Natalizumab is an option for the treatment only of rapidly evolving severe relapsing-remitting multiple sclerosis (RES). RES is defined by 2 or more disabling relapses in 1 year, and 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA127\">www.nice.org.uk/TA127</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75113",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1339",
                "label": "Natalizumub",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75113",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}